180 related articles for article (PubMed ID: 23329846)
1. Regulatory role of proteasome in determination of platelet life span.
Nayak MK; Kulkarni PP; Dash D
J Biol Chem; 2013 Mar; 288(10):6826-34. PubMed ID: 23329846
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
[TBL] [Abstract][Full Text] [Related]
3. Aspirin delimits platelet life span by proteasomal inhibition.
Nayak MK; Dash A; Singh N; Dash D
PLoS One; 2014; 9(8):e105049. PubMed ID: 25126950
[TBL] [Abstract][Full Text] [Related]
4. Sirtuin Inhibition Induces Apoptosis-like Changes in Platelets and Thrombocytopenia.
Kumari S; Chaurasia SN; Nayak MK; Mallick RL; Dash D
J Biol Chem; 2015 May; 290(19):12290-9. PubMed ID: 25829495
[TBL] [Abstract][Full Text] [Related]
5. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
6. The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB.
Fontanini A; Foti C; Potu H; Crivellato E; Maestro R; Bernardi P; Demarchi F; Brancolini C
J Biol Chem; 2009 Mar; 284(13):8369-81. PubMed ID: 19139105
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
8. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
[TBL] [Abstract][Full Text] [Related]
9. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dose-dependent effects of the proteasome inhibitor bortezomib in human platelets.
Koessler J; Etzel J; Weber K; Boeck M; Kobsar A
Eur J Pharmacol; 2016 Nov; 791():99-104. PubMed ID: 27568836
[TBL] [Abstract][Full Text] [Related]
12. Melatonin as a proteasome inhibitor. Is there any clinical evidence?
Vriend J; Reiter RJ
Life Sci; 2014 Oct; 115(1-2):8-14. PubMed ID: 25219883
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
14. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
15. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S
Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347
[TBL] [Abstract][Full Text] [Related]
18. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
19. BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.
Rapino F; Jung M; Fulda S
Oncogene; 2014 Mar; 33(13):1713-24. PubMed ID: 23644654
[TBL] [Abstract][Full Text] [Related]
20. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.
Avcu F; Ural AU; Cetin T; Nevruz O
Thromb Res; 2008; 121(4):567-71. PubMed ID: 17910980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
